¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º i#I+   
| %JJ S^)  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ |1d;0*HIgX  
; z_ZZ(W  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) q'kZ3 G   
/]=d Pb%  
1. ICAM-1 & [)1LRt_  
N>z<v\`  
2. interleukin 12(IL-12) \VL[,z=q.  
 5m,{?M`  
3. tumor infiltrating lymphocyte 2mS3gk  
}V.Wp6"S   
4. TCR/CD3 complex b&.j>=  
9z9z :PU  
5. hematopoietin receptor family Q9X7- \n  
FY%v \`@1*  
6. individual idiotype(IdI) +5pK[%k  
V>}@--$c-r  
7. integrin F"O{eK0T  
#W#GI"K  
8. colony-stimulatory factor (CSF) \tFg10  
\-k X-Tq  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 2XJn3wPi  
%=x|.e@J  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? 0'!v-`.  
Z5juyzj  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ }^uUw&   
dj*%^cI  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ;\7TQ9z  
y'?|#%D  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ 9"_JiX~3  
z'a#lA.$}  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 96 ;17h$  
`j*&F8}  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ _[8xq:G  
iorKS+w"  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) xB{0lI  
}J .f 5WaG  
3. immunoglobulin superfamily (IgSF) v0!>":  
f !t2a//  
4. selectin bHcb+TR3  
CBx1.xL  
5. anti-idiotypic antibody (¦ÁId) B e+'&+  
$Ch!]lJA  
6. major histocompatibility complex(MHC) E> Ukxi1  
:$d3}TjsA+  
7. immunotolerance ~k+"!'1  
#M *h)/d[A  
8. biological reponse modifier(BRM) x.ZV<tD i7  
\{J gjd  
9. immune reponse gene (Ir gene) 8r /]Q  
|RwpIe8~  
10. reshaped antibody (or reconstituted antibody) yrO'15TB  
3:jKuOX  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Acr\2!))  
F.c`0u;=  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ %j=dKd>  
QQP bKok>  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? a`(6hL3IT  
gT-'#K2qT  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ qdh;zAMx  
qC?J `   
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? iaXNf ])?  
OQaM47"  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ bO1J#bcZ  
a#FkoA~M  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? VaQ>g*(I  
*MW)APw=  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ,WA7Kp9  
qu BTRW9  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ 62rTGbDbx  
)v;>6(  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? q7mqzMDk  
WK0?$[|=r  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ f7{E(,  
>8Zz<S&z  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: Z"'rc.>a  
1qbd6D|t  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: OP]=MZP|  
_IOeO  
ÃâÒßѧ \c/jp5=}  
#9}KC 9f  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© >T;"bc b  
-liVYI2s  
1. CD8 YNc%[S[u^1  
En 8-Hc#NC  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) f}^}d"& F  
yxQxc5/X)  
3. immunoglobulin fold(Ig fold) O^G/(  
$5yS`Iq S  
4. cadherin (Ca-dependent cell adhesion moleculers) J)A1`(x&T  
uljd)kLy4O  
5. idiotype-anti-idiotypic antibody immune network theory flIdL,  
VF!?B>  
6. HLA class II antigen R!W!8rr3  
` B) ~  
7. complementarity-determining region (CDR) ':!w%& \  
yeKzI~  
8. perforin(or pore-forming protein ,PFP) f% ZqK_CW  
3m#v|52oj  
9. high affinity IL-2 receptor Zw| IY9D  
d{hb gUSj  
10. artificial active immunization -Vn9YeH+  
);@Dr!H  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© jU)r~QhN  
9@./=5N~3  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ}+#-\a2  
24Z7;'  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 a-4'jT:  
m;WUp{'  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ -2o4v#d  
Tc,Bv7:  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ LVq3 R 8A  
699z@>$}  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ enj Ti5X  
\2U^y4K.  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ^HLi1w|  
y AU[A  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ :t?9$ dL  
[^A.$,  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 49bzHEqZ  
S+R<wv ,6  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ =#&K\  
jx!)N>  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ j.uN`cU!  
=8X`QUmT  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© n }7DL8  
bEV 9l  
1. immunoglobulin gene rearrangement mAhtC*  
e,={!P"f  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) 2*vOo^f  
Nb>|9nu O  
3. flow cytometry(FCM) -9~kp'_a  
*!,+%0  
4. carrier effect MX|CL{H  
8X!U tHml  
5. positive selection of T lymphocytes in thymus p/:)Z_  
},2-\-1  
6. mouse TH1(Th1) and TH2(Th2) subsets &32qv` V_  
k~>9,=::d  
7. perforin (pore-forming protein ,PFP) F@kOj*5,[  
ge`)sB,  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Fm3-Sn|Po  
?g}n$%*5y!  
9. SH-2(src-homology region 2) #StD]d  
XLwbA4ORq  
10. Ab2¦Â (internal image) kWF4k  
;*:d)'A  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© /_rQ>PgSZW  
UIvTC S  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? rwtSn?0z"  
LXVm0IOFF  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? =jkC]0qx  
;8 JJ#ED  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ@?!/Pl49R  
25l6@7q.  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ X9/V;!  
::dLOf8o  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ?#qA>:2,  
oZ& ns!#  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) //JF$o=) D  
req=w;E:  
ÃâÒßѧרҵ£º 022YuqL<v  
Gu V -[  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ %\}|&z6  
o2 W pi  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? NSOWn]E  
8doT`rI1  
´«È¾²¡Ñ§×¨Òµ£º 29Kuq;6  
4.,e3  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ j5R= K*y  
lBR6O!sBP  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ gET& +M   
iEr|?,  
Ïû»¯×¨Òµ£º Y">Q16(  
3 a:(\:?z  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ T)3#U8sT  
u,PrEmy-  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? bC$n+G>6k  
Cs^o- g!L  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ r;y&Wa  
KofjveOiC  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© \tyL`& )  
;1NZY.pyc  
1. Fas(CD95)/FasL *7ap[YXZ\w  
\z:p"eua z  
2. common chain of cytokine receptor G2;Uv/vR  
SQvicZAN)`  
3 . TCR/CD3 complex i/C#fIB2  
U(3LeS;mr  
4. negaive selection of thymocytes 1ikkm7  
$]|_xG-6{  
5. artificial active immune Oq*a4_R'YV  
*%B%BJnX  
6. anti-idiotypic K._1sOw'"Y  
sFSrMI#R  
7. IgSF )lB-D;3[_  
,m3AVHa*G  
8. Integrin zFP}=K:o)  
 P/n XY  
9. chemokine 3i >$g3G  
$T;3*D90  
10. B7/CD28 bTO$B2eh|  
#0!C3it6c  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© _32ltnBX  
A.35WGu&:  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ MAJvjgd ..  
kZUuRB~om  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 _'2r=a#`  
p&vQ* }  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ [USXNe/  
(9Hc`gd)p  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ eH qf3f   
Q=uwmg86  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ &hV;3";  
tG%R_$*  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ FAPgXmFzx  
Ig N,]y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Xk7zXah  
)h+JX8K)l  
1. B7/CD28 K VQZ  
>!bYuVHA  
2. Th1 subset Y J1P5u:  
NA\,o;ka  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ghms-.:b8  
'JkK0a2D  
4. antibody affinity maturation @B&hR} 4  
q!O~*   
5. AP-1 |/p ^e  
-P.) 0d(  
6. single chain variable fragment£¨ScFv£© (AwbZn*  
L` Qiu@  
7. NK cell receptor F." L{g  
D_, 2z  
8. Zinkernagel-Doherty phenomenon &VQwuO  
7 51\K`L  
9. Ig fold d6M d~$R  
y<;#*wB  
10. CD40/CD40L '4O1Y0K  
7J 0!v q  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© W cqYpPv  
0} {QQB  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ P@*whjPmo  
xvrCm`3n@  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ^l iyWl  
ap=M$9L'  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ 43P?f+IYrk  
A4SM@ry  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ =;T971L`  
T=>&`aZH  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Y> 7/>x6  
T4Zp5m")  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ Bj\0RmVa1  
h#`qEK&u  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ ;=_KLG <  
6wxQ_Qz:Q  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© rJg! 2  
RL>[t  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© -i 6<kF-W  
*t*yozN  
1.Co-stimulators (or co-stimulating molecules) c%v%U &  
sLB{R#Pt  
2.NK-kB F lbL`@4M  
iD{;!dUZ  
3.Immunoglobulin superfamily "Tfbd^AU  
=f{r+'[;^  
4.antigen-presenting cell (APC) +[D=2&tmk  
4Tq%V|5"&  
5.death domain D'A)H  
C2!POf;GdN  
6.CCR and CXCR Yuh t<:`  
Cee?%NaTS  
7.Lectin (or mitogen) w^P4_Yr  
>#xpg&2x  
8.Clusters of differentiation, CD) *I> 1O*  
>Rx^@yQ!+z  
9.B7 family : h-N  
+D$\^ <#  
10.Cytotoxic T lymphocyte, CTL) "r.pU(uxt  
~Kt.%K5lgt  
11.IL-15 and IL-15 receptor (IL-15R) {:'e H  
orEwP/L:  
12.MHC restriction e7 5*84  
=yvyd0|35  
13.Affinity-chromatography eK4\v:oG1  
Q%q_  
14.Cyctosprin A, CsA D4;V8(w=#  
~@TNVkw  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) (<2PhJ|  
=U3 !D;XP  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© b pExYyt  
s+o/:rrx Y  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 9C3q4.$D  
#ZF|5 r +  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ #![b9~%WTh  
VO[s:e9L  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 qdNYY&6>?u  
(&+ ~hW5d  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© )O2giVq7[0  
p\1[cz)B  
ÃâÒßѧרҵ£º q"`1cFD  
<~vamim#K  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ B k#68p  
r9z/hm}E  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ #Ubzh`v  
ZGe+w](  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ >jRz4%  
lMF j"x\  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) _~| j~QE]  
Quc9lL  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) D />REC^  
x]XhWScr '  
1. ADCC(antibody dependent cell-mediated cytotoxicity) )9{?C4NQ  
O jr{z  
2. »·æß¾úËØ(cyclosporin) v/}M _E  
-U'6fx) +  
3. KIR(killer cell inhibitory receptor) 2BsMFMIw1  
rwv_ RN  
4. HLDA(human leucocyte differentiation antigen) Ng0V&oDI  
M g1E1kXe  
5. Interleukin 18(IL-18) n!~{4 uUW  
& d[&8V5S  
6. ÕûºÏËØ(integrin) HhH[p E  
~^w;`~L  
7. Fas/FasL F !tn|!~  
%o.{h  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) l5l:'EY>  
{ckA  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) ?tQ UZO  
GX4# IRq  
10. Th1/Th2 ahU\(=  
bP`yLz  
11. »ùÒòÒßÃç(DNAÒßÃç) dUk^DI,:l  
t.v@\[{ -  
12. chemokines and chemokine receptor C6Ap  4  
\=?f4*4|/  
13. ÃâÒßÄÍÊÜ @f-0OX$*  
vClD)Ar  
14. ¹²´Ì¼¤·Ö×Ó uZ&,tH/  
Z f4Xt Yn  
15. ËÀÍö½á¹¹Óò(death domain) .ZJt  
aF1pq  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) \(R(S!xr_  
Q7gBx p  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? #*:y2W%H  
f>g>7OsD]  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠiEux`CcJ.  
U< |kA(5  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î .h-:) e*  
bEfxu;Su 3  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ;,}tXz  
7rw}q~CE5  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå { aqce g  
&EYO[~D06  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ \/I@&$"F  
nqg=I  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) O:"gJ4D  
f7mP4[+dS  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ `{s:lf  
5K|1Y#X  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿  }bz v&k  
NdZv*  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»